Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 4067 results found since Jan 2013.
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
Primary Prevention of Stroke is Strongly Correlated with Low-Density-Lipoprotein Cholesterol Reduction: A Meta-Regression Analysis
Statins have become the cornerstone of therapy for both primary and secondary prevention of cardiovascular (CV) and cerebrovascular diseases (CVD). Numerous studies and meta-analyses have documented these benefits independent of low-density-lipoprotein cholesterol (LDL-C) lowering. There are discrepant reports regarding the dependence of the stroke benefits on the baseline LDL-C levels. The relevance of LDL-C reduction from baseline in the era of pleiotropic benefits needs further exploration, especially, while comparing the primary stroke cohort with the secondary stroke prevention cohort.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Samit Ghosal, Krishna G Seshadri Tags: Lipid Management in Special Populations Source Type: research
Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):36-43. doi: 10.17116/jnevro202312306136.ABSTRACTHigh and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary preventi...
Source: Atherosclerosis - June 29, 2023 Category: Cardiology Authors: A A Kulesh S N Yanishevskiy D A Demin L I Syromyatnikova O I Vinogradov Source Type: research
More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL & lt;70 mg/dL After a Stroke
CONCLUSIONS: In this post hoc analysis of the TST trial, targeting an LDL cholesterol of <70 mg/dL reduced the risk of primary outcome compared with 100±10 mg/dL provided LDL cholesterol reduction from baseline was superior to 50%, thereby suggesting that the magnitude of LDL cholesterol reduction was as important to consider as the target level to achieve.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875; https://clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:37376989 | DOI:10.1161/STROKEAHA.123.042621
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Pierre Amarenco Philippa C Lavall ée Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Contemporary Treatment and Outcome of Patients with Ischaemic Lower Limb Amputation: A Focus on Sex Differences
CONCLUSION: Patients undergoing ischaemic LLA still have a poor prognosis marked by high rates of recurrent cardiovascular and limb events resulting in > 50% mortality within two years. The continuous lack of guideline recommended therapies, particularly in women, may be associated with the persisting poor outcome, necessitating urgent further investigation.PMID:37355161 | DOI:10.1016/j.ejvs.2023.06.018
Source: PubMed: Eur J Vasc Endovasc ... - June 24, 2023 Category: Surgery Authors: Lena Makowski Christiane Engelbertz Jeanette K öppe Patrik Dr öge Thomas Ruhnke Christian G ünster Joachim Ger ß Eva Freisinger Nasser Malyar Holger Reinecke Jannik Feld Source Type: research
Neuroprotector Hopeful in Stroke; Late-Pandemic STEMIs; Exercise vs Risky Carotids?
(MedPage Today) -- In the CLEAR Outcomes trial, bempedoic acid (Nexletol) reduced cardiac events to a similar extent as statins, according to a secondary analysis presented at ENDO 2023.
The TLR4 antagonist ApTOLL showed promise as a neuroprotectant...
Source: MedPage Today Cardiovascular - June 20, 2023 Category: Cardiology Source Type: news
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
